Dual Glucose-Ketone Wearable Brings Earlier Metabolic

Medically reviewed | Published: | Evidence level: 1A
The FDA has authorized the Libre Duo 10 Day Continuous Dual Glucose Ketone Monitoring System for people aged 2 years and older with diabetes. Continuous access to both measurements could help families recognize rising ketones sooner, although suspected diabetic ketoacidosis still requires urgent clinical assessment.
📅 Published:
Reviewed by iMedic Medical Editorial Team
📄 Pediatric Health

Quick Facts

Minimum Age
2 years and older
Measurements
Glucose plus ketones
Wear Period
Up to 10 days

How Does Continuous Glucose and Ketone Monitoring Work?

Quick answer: The wearable measures glucose and ketone trends continuously, allowing users to see metabolic changes without relying solely on separate intermittent tests.

Glucose monitoring shows whether blood sugar is rising or falling, while ketone monitoring can reveal that the body is increasingly using fat for energy because it lacks sufficient effective insulin. Elevated ketones can develop during illness, missed insulin doses, insulin-pump interruption or other periods of metabolic stress.

Combining both measurements may provide more useful context than either value alone. High glucose without rising ketones and rising ketones during illness can require different responses, but users must follow the device instructions and their individualized diabetes plan rather than interpreting sensor data in isolation.

Could the Wearable Help Prevent Diabetic Ketoacidosis?

Quick answer: Earlier recognition of rising ketones may support faster action, but the device has not eliminated the need for emergency evaluation when diabetic ketoacidosis is suspected.

Diabetic ketoacidosis, or DKA, occurs when severe insulin deficiency leads to ketone accumulation and metabolic acidosis. Warning signs can include nausea, vomiting, abdominal pain, deep or rapid breathing, dehydration, unusual sleepiness and confusion. Children can deteriorate quickly, making timely recognition and treatment especially important.

A continuous ketone trend could prompt users to confirm concerning findings, administer insulin according to their sick-day plan, maintain appropriate fluids and contact their diabetes team. However, DKA is diagnosed through clinical assessment and laboratory testing; a wearable reading alone cannot confirm or rule out the condition.

What Should Parents Know Before Using a Dual Sensor?

Quick answer: Families need training on alerts, sick-day care and situations in which symptoms should outweigh a reassuring sensor reading.

Parents and caregivers should understand how to respond to rising glucose, rising ketones, sensor errors and readings that do not match the child's symptoms. Diabetes teams can provide written guidance covering illness, vomiting, insulin-pump failure, confirmatory testing and emergency thresholds.

The technology may reduce the burden of repeated separate ketone checks, but it does not replace insulin, routine diabetes care or clinical judgment. Vomiting, breathing difficulty, confusion, severe weakness or other signs of DKA require urgent medical help even when sensor information is incomplete or appears reassuring.

Frequently Asked Questions

The FDA authorization covers people aged 2 years and older who are living with diabetes. Individual suitability should be discussed with a diabetes clinician.

No. It provides glucose and ketone measurements, but DKA diagnosis requires evaluation of symptoms, acid-base status and other laboratory findings.

Yes. Backup glucose and ketone testing may be needed when readings conflict with symptoms, the sensor is unavailable or a diabetes care plan calls for confirmation.

References

  1. U.S. Food and Drug Administration. FDA Authorizes First Wearable Device That Continuously Monitors Both Ketone Levels and Blood Sugar. August 29, 2026.
  2. American Diabetes Association. Standards of Care in Diabetes—2026. Diabetes Care. 2026.
  3. International Society for Pediatric and Adolescent Diabetes. Clinical Practice Consensus Guidelines 2022: Diabetic ketoacidosis and hyperglycemic hyperosmolar state. Pediatric Diabetes. 2022.